Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Yoshikazu Yonemitsu has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. KELLY, ROBERT M is the busiest examiner with 1 pending office action. This indicates that each of the current applications is being reviewed in a unique technical and personnel environment within the biotechnology sector.
The involvement of 2 distinct examiners for 2 pending office actions means that there is no overlap in the individuals reviewing the current filings. For a practitioner, this requires managing 2 different examiner relationships simultaneously. Because the workload is also split between 2 distinct art units, the procedural requirements and timelines may differ for each of the 2 pending office actions.
KELLY, ROBERT M, identified as the busiest examiner with 1 pending office action, handles only half of the current pending workload. This decentralized structure in the Biotechnology & Pharmaceuticals area suggests that the patent strategy must be highly adaptable. The 2 distinct art units further diversify the potential prosecution outcomes for the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17441439 | A METHOD FOR PROVIDING IMMUNE CELLS | WESTON, ALYSSA G | 1d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17441439 | A METHOD FOR PROVIDING IMMUNE CELLS | WESTON, ALYSSA G | 1d overdue |
| 18602312 | Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18602312 | Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same | KELLY, ROBERT M | 1638 | §112Other | Non-Final OA | — | Pending | Mar 12, 2024 |
| 17441439 | A METHOD FOR PROVIDING IMMUNE CELLS | WESTON, ALYSSA G | 1633 | §102§103§112 | Final Rejection | 1d overdue | Pending | Sep 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial